Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing

Prostate. 2024 Oct;84(14):1290-1300. doi: 10.1002/pros.24772. Epub 2024 Jul 25.

Abstract

Purpose: Both lower urinary tract symptoms (LUTS) and prostate cancer (PCa) are common in elderly men. While LUTS are generally due to a benign etiology, they may provoke an evaluation with prostate-specific antigen (PSA), which can lead to a cascade of further testing and possible overdiagnosis in patients with competing risks. There is limited patient and provider understanding of the relationship between LUTS and PCa risk, and a lack of clarity in how to evaluate these men to balance appropriate diagnosis of aggressive PCa with avoidance of overdiagnosis.

Methods: A literature review was performed using keywords to query the electronic database PubMed. All articles published before November 2023 were screened by title and abstract for articles relevant to our subject.

Results: Epidemiological studies suggest that LUTS and PCa are largely independent in elderly men. The best available tools to assess PCa risk include PSA permutations, novel biomarkers, and imaging, but there are limitations in older men based on lack of validation in the elderly and unclear applicability of traditional definitions of "clinically significant" disease. We present a three-tiered approach to evaluating these patients.

Conclusion: Elderly men commonly have LUTS as well as a high likelihood of indolent PCa. A systematic and shared decision-making-based approach can help to balance objectives of appropriate detection of phenotypically dangerous disease and avoidance of over-testing and overdiagnosis.

Keywords: lower urinary tract symptoms; prostate cancer; prostate‐specific antigen; prostatic neoplasms.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Early Detection of Cancer / methods
  • Humans
  • Lower Urinary Tract Symptoms* / diagnosis
  • Male
  • Prostate-Specific Antigen* / blood
  • Prostatic Neoplasms* / diagnosis

Substances

  • Prostate-Specific Antigen